(S)-2-(3,4-dichlorophenyl)butanoic acid | 888499-95-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-2-(3,4-dichlorophenyl)butanoic acid
• 英文别名: (2S)-2-(3,4-dichlorophenyl)butanoic acid
• CAS: 888499-95-4
• 化学式: C₁₀H₁₀Cl₂O₂
• 分子量: 233.094
• InChiKey: AGRABJOLCYBTRV-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-2-(3,4-dichlorophenyl)butanoic acid 、 在 N-甲基吗啉 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 作用下， 以 乙腈 为溶剂， 反应 1.0h， 生成 2-(S)-N-[(5-cyclopropyl-2-methoxypyridin-3-yl)methyl]-2-(3,4-dichlorophenyl)butanamide
  参考文献：
  名称：

  WO2006/60108

  摘要：

  公开号：
• 作为产物：
  描述：

  (2S)-2-(3,4-dichlorophenyl)-N-[(1S,2S)-1-hydroxy-1-phenylpropan-2-yl]-N-methylbutanamide 在 硫酸 、 水 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 (S)-2-(3,4-dichlorophenyl)butanoic acid
  参考文献：
  名称：

  WO2006/60108

  摘要：

  公开号：

文献信息

• Highly Enantioselective Direct Alkylation of Arylacetic Acids with Chiral Lithium Amides as Traceless Auxiliaries
  作者：Craig E. Stivala、Armen Zakarian

  DOI：10.1021/ja205107x

  日期：2011.8.10

  A direct, highly enantioselective alkylation of arylacetic acids via enediolates using a readily available chiral lithium amide as a stereodirecting reagent has been developed. This approach circumvents the traditional attachment and removal of chiral auxiliaries used currently for this type of transformation. The protocol is operationally simple, and the chiral reagent is readily recoverable.

  已经开发出使用容易获得的手性氨基锂作为立体定向试剂通过烯二醇对芳基乙酸进行直接、高度对映选择性的烷基化。这种方法绕过了目前用于此类转化的手性助剂的传统附着和去除。该方案操作简单，手性试剂易于回收。
• N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators
  申请人：Kim Yuntae

  公开号：US20080124402A1

  公开（公告）日：2008-05-29

  Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
• WO2006/60108
  申请人：——

  公开号：——

  公开（公告）日：——